Dual inhibition of CB₁ receptors and iNOS, as a potential novel approach to the pharmacological management of acute and long COVID-19.

ABSTRACT: COVID-19 (SARS-CoV-2) causes multiple inflammatory complications, resulting not only in severe lung inflammation but also harm to other organs. Although the current focus is on the management of acute COVID-19, there is growing concern about long-term effects of COVID-19 (Long Covid), such as fibroproliferative changes in the lung, heart and kidney. Therefore, the identification of therapeutic targets not only for the management of acute COVID-19 but also for preventing Long Covid are needed, and would mitigate against long-lasting health burden and economic costs, in addition to saving lives. COVID-19 induces pathological changes via multiple pathways, which could be targeted simultaneously for optimal effect. We discuss the potential pathologic function of increased activity of the endoc

SUBMITTER: Cinar R 

PROVIDER: S-EPMC8251289 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature